NCT04623099 (PrEcISE) is a Phase 4 clinical trial of Escitalopram in Anxiety, sponsored by University of Cincinnati.

Who is sponsoring NCT04623099?

NCT04623099 is sponsored by University of Cincinnati.

What drugs are being tested in NCT04623099?

Interventions in NCT04623099: Escitalopram.

Is NCT04623099 still recruiting?

NCT04623099 is currently recruiting now. Last updated 29 August 2024.

Last reviewed 2024-08-29 · How we verify

NCT04623099: PrEcISE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)

Recruiting now Phase 4 Last updated 29 August 2024

What this trial tests

Phase 4 trial testing Escitalopram in Anxiety in 132 participants. Currently enrolling.

Timeline

8 March 2021

Primary endpoint
30 June 2026

1 December 2026

Quick facts

Lead sponsor	University of Cincinnati
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	132
Start date	8 March 2021
Primary completion	30 June 2026
Estimated completion	1 December 2026
Sites	1 location across United States

Drugs / interventions tested

Escitalopram (escitalopram) — full drug profile →

Conditions studied

Anxiety — all drugs for Anxiety →

Sponsor

University of Cincinnati

Who can join

Adults 12 to 17, any sex, with Anxiety. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This double-blind, 12-week study will consist include132 anxious youth who are randomized (1:1) to standard or pharmacogenetically-guided escitalopram dosing. Block randomization (1:1) will be stratified by sex and metabolizer status.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The emergence, implementation, and future growth of pharmacogenomics in psychiatry: a narrative review.
Bousman CA, Maruf AA, Marques DF, Brown LC, et al · · 2023 · cited 37× · PMID 37772416 · DOI 10.1017/s0033291723002817
Pharmacogenetically Guided Escitalopram Treatment for Pediatric Anxiety Disorders: Protocol for a Double-Blind Randomized Trial.
Strawn JR, Poweleit EA, Mills JA, Schroeder HK, et al · · 2021 · cited 9× · PMID 34834540 · DOI 10.3390/jpm11111188
A Double-Blind Randomized Trial to Investigate Mechanisms of Antidepressant-Related Dysfunctional Arousal in Depressed or Anxious Youth at Familial Risk for Bipolar Disorder.
Honeycutt DC, DelBello MP, Strawn JR, Ramsey LB, et al · · 2022 · cited 4× · PMID 35743790 · DOI 10.3390/jpm12061006

Verify or expand the search:

Other trials of Escitalopram

Trials testing the same drug.

NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT07331987 — Efficacy and Safety of Probiotics for Anxiety Depression · NA · not yet recruiting
NCT06216535 — Escitalopram in Asthma Patients With Frequent Exacerbation · Phase 2 · recruiting
NCT06937476 — Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole · NA · active not recruiting
NCT05603104 — Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First- · Phase 3 · recruiting

Other recruiting trials for Anxiety

Currently open trials in the same condition.

NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT07522944 — AI-Guided Relaxation for Hemodialysis Anxiety · NA · recruiting
NCT07466875 — Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients · NA · recruiting
NCT07425951 — Building Cognitive Behavioural Skills With StoryBooks to Reduce Emotional Difficulties in Kindergarten Years · NA · recruiting
NCT07473505 — Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospect · recruiting

Other University of Cincinnati trials

Trials by the same sponsor.

NCT05605366 — Minocycline In Neurocognitive Outcomes - Sickle Cell Disease · Phase 1 · not yet recruiting
NCT07528638 — Intraoperative Neuromonitoring (IONM) and Bipolar Electrocautery (BE) During Axillary Lymph Node Dissection (ALND) · NA · not yet recruiting
NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment · NA · recruiting
NCT07447895 — Early Pelvic Floor Physical Therapy for Women Undergoing Pelvic Radiation for Gynecologic Malignancies · NA · not yet recruiting
NCT07231588 — Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04623099 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Cincinnati
Last refreshed: 29 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04623099.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing